Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
The Lancet (British edition), 2017-03, Vol.389 (10074), p.1103-1113 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 18, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30060-0 ;PMID: 28185672 ;CODEN: LANCAO
Full text available